Abstract:Seasonal allergic conjunctivitis (SAC) is caused by seasonal allergens and usually manifests as ocular itching and bulbar conjunctival injection (redness). Treatment options for SAC include corticosteroids and dual-acting antihistamine and mast-cell stabilizers.Our objective was to compare the efficacy and tolerability of loteprednol etabonate (LE), a C-20 ester-based corticosteroid, with those of olopatadine, a dual-acting antihistamine mast-cell stabilizer, in Chinese patients.This was a multicenter, randomized, investigator-masked, parallel group study. Patients with acute SAC experiencing grade 4 ocular itching and grade 2 or higher bulbar conjunctival injection received either LE suspension 0.2% QID at 4-hour intervals or olopatadine solution 0.1% BID at 6- to 8-hour intervals bilaterally for 15 days. Primary efficacy end points included the change from baseline (CFB) in ocular itching and bulbar conjunctival injection at day 15. The primary analysis tested the noninferiority of LE suspension 0.2% to olopatadine solution 0.1%. Tolerability outcomes included the incidence of adverse events (AEs), biomicroscopy findings, visual acuity, and intraocular pressure.A total of 300 patients were randomly assigned, and 293 were included in the per-protocol population (LE, n = 147; olopatadine, n = 146). Mean (SD) CFB at day 15 in the LE and olopatadine treatment groups, respectively, was -3.74 (0.47) and -3.28 (0.91) for ocular itching and -1.91 (0.52) and -1.71 (0.59) for bulbar conjunctival injection. The 95% CI for the differences in CFB in ocular itching (-0.59 to -0.27) and bulbar conjunctival injection (-0.27 to -0.08) was less than the prespecified noninferiority limit of 0.3. Treatment differences in CFB were significantly better with LE compared with olopatadine for both end points (P ≤ 0.0006). Ocular AEs were few and similar between treatment groups. There were no clinically significant biomicroscopy or visual acuity findings, and no patient experienced a clinically significant increase in intraocular pressure (≥10 mm Hg).Results of this investigator-masked study with Chinese patients suggest LE suspension 0.2% was noninferior to olopatadine solution 0.1% for the treatment of SAC. Both LE suspension 0.2% and olopatadine solution 0.1% were well tolerated. ClinicalTrials.gov identifier: NCT01435460.

A Multi-Center Clinical Trial of Tranilast Drops for Allergia Conjunctivitis

Varenicline Solution Nasal Spray for Dry Eye Disease in Chinese Patients: a Randomized Phase 3 Trial

Efficacy of 3% diquafosol combined with azelastine hydrochloride in allergic conjunctivitis patients with dry eye

Effect of Tong Qiao drops on the expression of eotaxin, IL-13 in the nasal mucosa of rats with allergic rhinitis.

Perfluorohexyloctane Eye Drops for Dry Eye Disease Associated With Meibomian Gland Dysfunction in Chinese Patients: A Randomized Clinical Trial.

Alleviation of Allergic Rhinoconjunctivitis Symptoms in Participants Treated with a 0.005% Tacrolimus Eye-Drop Solution

Clinical assessment of 0.1% Diclofenac Sodium eye drops on the treatment of acute allergic conjunctivitis

A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis.

Randomized Controlled Clinical Trial on Azelastine Hydrochloride Tablet Versus Loratadine in the Treatment of Allergic Rhinitis

Efficacy and Safety of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray in Treating Allergic Rhinitis: a Randomized Controlled Trial

Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients.

Clinical Efficacy of Ketotifen Furnarate 0.025%ophthalmic Solution in Alleviating Ocular Itching and Conjunctival Hyperemia in Pafients with Seasonal Allergic Conjtmctivitis

Acupuncture for Moderate to Severe Allergic Rhinitis: A Non-Randomized Controlled Trial.

Effect of co-administration of pranoprofen/emedastine difumarate eye drops on efficacy, inflammatory factors, tear film stability and immune function in children with allergic conjunctivitis

Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model

Evaluation of the Efficacy of Olopatadine Hydrochloride in the Treating Allergic Rhinitis:A Multicenter,Randomized,Double-blind,Double-dummy Study

Combination Therapy of 0.1% Fluorometholone and 0.05% Azelastine in Eyes with Severe Allergic Conjunctival Diseases: A Randomized Controlled Trial

Efficacy and safety of azithromycin eye drops in treatment of bacterial conjunctivitis: a Meta-analysis

Treatment of Allergic Rhinitis with Fexofenadine Hydrochloride: a Multicenter Clinical Trial

Evaluation of the Efficacy and Safety of Desloratadine in Treating Allergic Rhinitis

Efficacy and safety of pemirolast potassium in comparison with tranilast for bronchial asthma and allergic rhinitis:a multicenter,randomized,double-blind,double-dummy,parallel-group trial